Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.43 |
| ▸ | RNASEH1 | O60930 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23930862 | 0.76 | PIN1 (0.44) | RNASEH1PIN1 | |
| SCHEMBL6469854 | 0.73 | HCAR2 (0.44) | HCAR2LMNAPIN1HSD17B10 | |
| SCHEMBL13056608 | 0.70 | CDC7 (0.36) | HCAR2HSD17B10 | |
| SCHEMBL7146649 | 0.68 | PIN1 (0.47) | HCAR2RNASEH1PIN1 | |
| SCHEMBL2804373 | 0.68 | PIN1 (0.44) | HCAR2RNASEH1LMNAPIN1 | |
| SCHEMBL19366154 | 0.66 | PIN1 (0.49) | HCAR2RNASEH1PIN1 | |
| SCHEMBL2821035 | 0.66 | PIN1 (0.49) | HCAR2RNASEH1PIN1 | |
| SCHEMBL29917975 | 0.64 | ALDH1A1 (0.38) | HCAR2RNASEH1PIN1 | |
| SCHEMBL30503047 | 0.64 | RNASEH1 (0.60) | RNASEH1 | |
| SCHEMBL7416029 | 0.64 | CYP1A2 (0.30) | PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1025085-B1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO MCNEIL PHARM INC (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | HUTCHINGS RICHARD H (US) | 2002-11-07 | — | — | US | disclosed |
| US-6384035-B1 | TREATING A DISEASE MEDIATED BY THE .ALPHA.-1.SUB.A ADRENERGIC RECEPTOR COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | ADRA1A, ADRB1, ADRA1D | HCAR2 97/4885RNASEH1 2517/4885LMNA 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.